4 min listen
Unavailable
Currently unavailable
While tech waffles on going public, biotech IPOs boom
Currently unavailable
While tech waffles on going public, biotech IPOs boom
ratings:
Length:
7 minutes
Released:
Jul 24, 2018
Format:
Podcast episode
Description
For people who make investment decisions based on revenues and projected earnings, biotech IPOs are kind of a non-starter. Not only are new market entrants universally unprofitable, most have zero revenue. Going public is mostly a means to raise money for clinical trials, with red ink expected for years to come. That pattern may be one reason the venture capital press,Crunchbase Newsincluded, tends to devote a disproportionately small portion of coverage to biotech IPOs.
Released:
Jul 24, 2018
Format:
Podcast episode
Titles in the series (100)
Social gaming platform Rec Room scores $20 million Series C by TechCrunch Startup News